Reducing residual risk for patients on statin therapy: the potential role of combination therapy.
Explore this paper's citation graph
Summary
The role of combination therapy in managing CAD and in achieving optional targets in high-risk patient populations is discussed and appears most appropriate for patients with a high rate of events of residual risk despite optimal statin therapy.
- Type
- article
- Published
- 2005-11-07
- Cited by
- 92
- References
- 36
- OpenAlex
- https://openalex.org/W16291008
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:29735224
Keywords
Humanities, Art, Valencia, Biology
References
- Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels.
- MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial.
- Recommendations for the management of dyslipidemia and the prevention of cardiovascular disease: summary of the 2003 update.
- Results of the National Cholesterol Education (NCEP) Program Evaluation ProjecT Utilizing Novel E-Technology (NEPTUNE) II survey and implications for treatment under the recent NCEP Writing Group recommendations.
- Joint Effects of Serum Triglyceride and LDL Cholesterol and HDL Cholesterol Concentrations on Coronary Heart Disease Risk in the Helsinki Heart Study: Implications for Treatment
- Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (the SAFARI trial).
- The ALLHAT lipid lowering trial--less is less.
- Clinical significance of statin pleiotropic effects: hypotheses versus evidence.
- The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report.
- Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial.
- Joint Effects of Serum Triglyceride and LDL Cholesterol and HDL Cholesterol Concentrations on Coronary Heart Disease Risk in the Helsinki Heart Study
- Effect of coadministration of ezetimibe and simvastatin on high-sensitivity C-reactive protein.
- Risk of adverse events with fibrates.
- High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study.
- Oxidized-LDL through LOX-1 increases the expression of angiotensin converting enzyme in human coronary artery endothelial cells.
- Baseline characteristics in the Cholesterol and Recurrent Events (CARE) trial of secondary prevention in patients with average serum cholesterol levels.
- Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin.
- Statin trials and goals of cholesterol-lowering therapy.
- National cross sectional survey to determine whether the decision to delivery interval is critical in emergency caesarean section
- Natural statins and stroke risk.
Cited by
- Efficacy and Safety of Coadministration of Fenofibrate and Ezetimibe Compared with Each as Monotherapy in Patients with Type IIb Dyslipidemia and Features of the Metabolic Syndrome
- Riconoscimento del rischio residuo
- Investigating the cholesterol-independent (pleiotropic) effects of selected hypolipidaemic agents in functional and dysfunctional endothelial cells
- Intolerance to statins: a challenge in clinical practice
- Safety of a Fixed-Dose Combination of Fenofibrate/Pravastatin 160 mg/40 mg in Patients with Mixed Hyperlipidaemia
- Lipoprotein-associated phospholipase A2 (Lp-PLA2) Impact and role as cardiovascular risk marker
- Cardiovascular risk factors regulate the expression of vascular endothelin receptors.
- Systematic review on evidence of the effectiveness of cholesterol-lowering drugs
- Safety of lovastatin/extended release niacin compared with lovastatin alone, atorvastatin alone, pravastatin alone, and simvastatin alone (from the United States Food and Drug Administration adverse event reporting system).
- Drug Insight: the role of statins in combination with ezetimibe to lower LDL cholesterol
- Prevalence, Predictors, and Impact of Low High-Density Lipoprotein Cholesterol on in-Hospital Outcomes Among Acute Coronary Syndrome Patients in the Middle East
- Effects of ezetimibe, simvastatin and ezetimibe/simvastatin on correlations between apolipoprotein B, LDL cholesterol and non-HDL cholesterol in patients with primary hypercholesterolemia.
- Nonhormonal Drug Eases Vasomotor Symptoms
- Perspectives of the non-statin hypolipidemic agents.
- Novel cholesterol biosynthesis inhibitors targeting human lanosterol 14alpha-demethylase (CYP51).
- Reducing vascular events risk in patients with dyslipidaemia: an update for clinicians
- Concordance between plasma apolipoprotein B levels and cholesterol indices among patients receiving statins and nonstatin treatment: Post-hoc analyses from the U.K. InPractice study.
- Therapeutic association of atorvastatin and insulin in cardiac ischemia: study in a model of type 2 diabetes with hyperlipidemia.
- Fenofibrate
- Efficacy and tolerability of atorvastatin/fenofibrate fixed-dose combination tablet compared with atorvastatin and fenofibrate monotherapies in patients with dyslipidemia: a 12-week, multicenter, double-blind, randomized, parallel-group study.
Related papers
No related papers recorded.